The Mayo Clinic Cancer Center (MCCC) is poised to provide an exceptional career development experience for academic oncologists and translational cancer researchers who seek to establish a career in patient- oriented research. A National Cancer Institute (NCI)-designated comprehensive cancer center with 40+ years of continuous funding, the MCCC remains at the epicenter of high-quality, practice-changing research. Its funding portfolio includes an NCI-funded Phase I grant; a Phase II contract; 5 Specialized Programs of Research Excellence (SPORE's) in cancers of the brain, breast, ovary, pancreas as well as lymphomas (the latter is a 2-institution, shared SPORE); and multiple investigator-initiated grants. It maintains strong ties to the national cancer clinical trals networks, including the Alliance. It is home to an NCI Community Oncology Research Program (NCORP) grant and a Cancer Prevention Network (CPN) contract. Similarly, the Mayo Graduate School of Medicine is one of the largest training programs in the world. In this application, the MCCC seeks to renew the Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic, requesting 5 positions at any one time for a dual track, M.D. and Ph.D. career development program. The MCCC has been privileged to hold this award since 2001. To date, all 33 Calabresi scholars remain engaged in translational cancer research; all have applied for peer-reviewed research funding; 94% have secured such funding; 10 have acquired R01 or R01-equivalent funding as a principal investigator (5 this past grant cycle); some hold leadership positions in academic oncology; and all have published in cancer therapeutics, cumulatively amassing 1500+ publications during and after their scholar tenure. In this application, scholars must focus on 1 of 5 research tracks that align with MCCC Programs: Gastrointestinal Malignancies, Hematology, Neuro-Oncology, Novel Therapeutics, or Women's Cancers. Multidisciplinary mentoring teams will work with each scholar as he/she completes coursework, embarks upon hands-on patient-oriented research, and strives for career independence. Administrative infrastructure consists of a principal investigator who has been committed to this training program since its inception, an internal advisory committee comprised of accomplished leaders/mentors within the MCCC, and an external advisory committee selected for its interest and renowned expertise in training a diverse academic work force in cancer research. The MCCC seeks to train another generation of investigators who will conduct cutting edge, hypothesis-driven, practice-changing research in cancer therapeutics.
The Mayo Clinic Cancer Center (MCCC) seeks to renew the 'Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic,' requesting 5 positions at any one time for a dual track, M.D. and Ph.D. career development program. Since 2001, the MCCC has trained 33 successful Calabresi scholars and seeks to train another generation of investigators who will conduct cutting edge, hypothesis-driven, practice- changing research in cancer therapeutics.
|Durani, Urshila; Gallo de Moraes, Alice; Beachey, Joel et al. (2018) Epithelioid angiosarcoma: A rare cause of pericarditis and pleural effusion. Respir Med Case Rep 24:77-80|
|Parikh, Sameer A; Chaffee, Kari G; Larson, Melissa C et al. (2018) Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica 103:e237-e240|
|Yan, Yiyi; Cao, Siyu; Liu, Xin et al. (2018) CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 3:|
|Mansfield, Aaron S; Peikert, Tobias; Smadbeck, James B et al. (2018) Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. J Thorac Oncol :|
|Parikh, Sameer A (2018) Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J 8:93|
|Hampel, Paul J; Larson, Melissa C; Kabat, Brian et al. (2018) Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol 183:421-427|
|Glumac, Paige M; Forster, Colleen L; Zhou, Hong et al. (2018) The identification of a novel antibody for CD133 using human antibody phage display. Prostate 78:981-991|
|Yan, Yiyi; Kumar, Anagha Bangalore; Finnes, Heidi et al. (2018) Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol 9:1739|
|Miao, Diana; Margolis, Claire A; Gao, Wenhua et al. (2018) Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359:801-806|
|Mansfield, Aaron S; Peikert, Tobias; Vogelzang, Nicholas J et al. (2018) Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. Mayo Clin Proc 93:1026-1033|
Showing the most recent 10 out of 243 publications